BraTioUS-DB: Brain Tumor Intraoperative Ultrasound Database

Sponsor
Hospital del Río Hortega (Other)
Overall Status
Recruiting
CT.gov ID
NCT05062772
Collaborator
(none)
100
3
18.2
33.3
1.8

Study Details

Study Description

Brief Summary

Predicting the survival of patients diagnosed with glioblastoma (GBM) is essential to guide surgical strategy and subsequent adjuvant therapies. Intraoperative ultrasound (ioUS) is a low-cost, versatile technique available in most neurosurgical departments. The images from ioUS contain biological information possibly correlated to the tumor's behavior, aggressiveness, and oncological outcomes. Today's advanced image processing techniques require a large amount of data. Therefore, the investigators propose creating an international database aimed to share intraoperative ultrasound images of brain tumors. The acquired data must be processed to extract radiomic or texture characteristics from ioUS images. The rationale is that ultrasound images contain much more information than the human eye can process. Our main objective is to find a relationship between these imaging characteristics and overall survival (OS) in GBM. The predictive models elaborated from this imaging technique will complement those already based on other sources such as magnetic resonance imaging (MRI), genetic and molecular analysis, etc. Predicting survival using an intraoperative imaging technique affordable for most hospitals would greatly benefit the patients' management.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Ultrasound

Detailed Description

The investigators plan to carry out a multicentre retrospective study of patients operated with GBM diagnosis between January 2018 and January 2020, in order to set the base for future prospective collection of patients. All cases with an ioUS study will be included. All patients must count with B-mode modality. After an pseudonymization process, the images will be uploaded to a private cloud server. Demographic, clinical, conventional radiological, and molecular variables (IDH, MGMT) will also be collected. OS will be defined as the time elapsed between the histopathological diagnosis and the patient's death. The acquired data must be processed to obtain a series of radiomic markers to perform the study. A pre-processing stage will be necessary (noise cleaning, despeckling, intensity normalization, filtering) to calculate radiomics measurements (histogram, volumetric, shape, texture, etc.). In the previous stage, a very high number of radiological features per subject will be calculated. Because the number of features is much higher than the data set, to avoid the curse of dimensionality, it will be necessary to reduce their number using feature selection and extraction techniques (standard in pattern recognition and radiomics) that allow choosing those characteristics (or transformations of them) that have greater discriminating power. A predictive model of survival will then be elaborated based on the features selected.

Hypotheses

Intraoperative ultrasound images in B-mode harbour tumor texture features correlated with overall survival in glioblastomas.

Objectives:
  • To determine the relationship between the radiomic features of intraoperative ultrasound B-mode and overall survival in glioblastomas.

  • Develop a predictive survival model using the texture features with the highest discriminatory power.

  • Validate the model against an external dataset and compare it with currently available predictive models.

  • Build a data set that allows exploring various image harmonization techniques that allow the reproducibility of our predictions.

  • Establish an international cooperation network (BraTioUS-DB) whose objective will be to interchange ultrasound images and clinical data of patients operated on for a brain tumor prospectively from its creation and start-up.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Predicting Overall Survival in Glioblastomas Using Radiomic Features of Intraoperative Ultrasound. A Proposal for the Creation of an International Database of Brain Tumor Ultrasound Images
Anticipated Study Start Date :
May 25, 2022
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
Nov 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Glioblastoma

Diagnostic Test: Ultrasound
Intraoperative ultrasound imaging

Outcome Measures

Primary Outcome Measures

  1. Overall survival [1 year]

    Overall survival in glioblastoma

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients operated between January 2018 and January 2020 with a pathological diagnosis of WHO grade IV astrocytoma (Glioblastoma).

  • Intraoperative ultrasound study that includes B-mode images

Exclusion Criteria:
  • Other histopathological diagnoses. Even though the international database will be established in such a way that other tumor types can be included prospectively.

  • Artifacts in ultrasound images that make their analysis impossible

  • Stereotactic biopsies.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione Irccs Istituto Neurologico "Carlo Besta" Milan Italy 20133
2 Unit of Neurosurgery, Department of Biomedicine Neurosciences and Advanced Diagnsotics, University of Palermo Palermo Italy 90100
3 University Hospital Rio Hortega Valladolid Spain 47012

Sponsors and Collaborators

  • Hospital del Río Hortega

Investigators

  • Principal Investigator: Santiago Cepeda, MD, PhD, Department of Neurosurgery University Hospital Río Hortega

Study Documents (Full-Text)

More Information

Additional Information:

Publications

Responsible Party:
Santiago Cepeda, Principal investigator, Hospital del Río Hortega
ClinicalTrials.gov Identifier:
NCT05062772
Other Study ID Numbers:
  • 21-PI085
First Posted:
Sep 30, 2021
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Santiago Cepeda, Principal investigator, Hospital del Río Hortega
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022